Introduction
In the early 1980s the pioneering work of Brenner and coworkers 1 originally demonstrated that angiotensin-converting enzyme (ACE) inhibition strongly prevented progressive renal disease in experimental models. Since then, this class of compounds has been studied, in experimental settings as well as in human studies, to better characterise their potential beneficial effects on the progression of proteinuric renal diseases with involvement of glomerular damage. Our group demonstrated, in the last two decades, 2 that blocking the action of angiotensin II (Ang II) with ACE inhibitors (ACE-I), or with antagonists of the Ang II receptor (AT 1 ), induces amelioration of glomerular selective properties towards circulating proteins, prevents proteinuria and exerts beneficial effects on the progression of renal disease. We suggested that these drugs exert renal protective effects by lowering the protein load of tubular cells, with consequent lower production of interstitial mediators of cell activation and pro-fibrotic agents by tubular cells, Benigni. 3, 4 This cascade of events, originally observed in experimental studies, is now largely confirmed by clinical studies as well as the clinical practice.
More recently, we and others focussed our attention on the possibility of using these two classes of drugs not only to slow the rate of progression of proteinuric renal diseases but also to induce regression of renal structural and functional changes [5] [6] [7] both in experimental and clinical settings. These new findings drew attention to the potential effects of blocking Ang II generation and action, and prompted us to investigate in more detail this tissue repair process. In this context several investigators are now studying molecular and cellular mechanisms that are triggered by ACE-Is and/or Ang II receptor antagonists (AIIAs).
In the following review, among other topics we discuss the pharmacological properties and renal effects of the AIIA telmisartan, a drug that has interesting properties in addition to its effects on Ang II antagonism and seems to be particularly promising in the protection of renal damage in selected types of renal disease.
Pharmacological properties of telmisartan
Several experimental and clinical studies have indicated that telmisartan is a potent and selective antagonist of AT 1 -receptors. This action is exerted in several tissues, in particular vascular smooth muscle cells and the adrenal gland. This strong inhibition of Ang II actions induced by telmisartan lowers arterial pressure and aldosterone secretion. As reviewed recently by Sharpe et al, 8 the high affinity of telmisartan for AT 1 -receptors is associated with negligible or marginal affinity for other known receptors (such as adenosine, adrenergic, dopaminergic, endothelin receptors and others). Kakuta and recently demonstrated that telmisartan is more efficacious AT 1 -receptor antagonist (AIIA) than other compounds currently used clinically. According to their in vitro evaluation, the mean dissociation rate constant of telmisartan is 0.003 min -1 while it averages 0.004, 0.005, 0.009 and 0.010 min -1 respectively for olmesartan, candesartan, valsartan and losartan. Similarly, telmisartan has a prolonged duration of action with a dissociation half-life longer than 200 minutes while the other compounds listed above showed dissociation half-lives averaging 166, 133, 70, 67 minutes respectively. In line with the in vitro evaluations it has also been shown that telmisartan has a long duration of action in the clinical setting without evidence of drug accumulation. 10 The elimination half-life of telmisartan is approximately 24-hours and is considerably longer than that observed with other AIIAs conventionally used. This favourable pharmacokinetic profile suggests a potential for prolonged and sustained reduction in blood pressure over the 24-hour cycle in comparison to other drugs of the same class, and these pharmacological effects are directly related to the compound since its primary metabolite has no detectable effect on Ang II receptors, or on blood pressure. 10 Available clinical studies have also shown that the effects of telmisartan on blood pressure and urinary albumin excretion are not related to polymorphism in angiotensinogen, ACE or AT 1 -receptor genes in hypertensive patients receiving chronic treatment with telmisartan for more than 12 months. 11 In theory, blockade of the AT 1 -receptor is expected to increase plasma renin activity (PRA) and Ang II levels, however, telmisartan in healthy volunteers as well as in hypertensive patients, did not induce significant changes in PRA, as compared to ACE-I treatment. 12 In recent years it has been suggested that some AT 1 -receptor antagonists, beside reducing blood pressure, might also improve insulin sensitivity. 13 In this regard, telmisartan has been demonstrated to act as a partial agonist of the peroxisomeactivated receptor-gamma (PPAR-γ), a nuclear transcription factor that regulates the metabolism of carbohydrates and lipids, and this effect seems to be independent of blood pressure reduction and also of AT 1 -receptor antagonism. The definition of this molecule as a selective PPAR-γ modulator is related to the fact that other compounds have been shown to induced stronger PPAR-γ activation with a different pattern in gene activation and transcription. A recent report by Schupp et al. 14 provided evidence for a direct interaction between some AIIAs and PPAR-γ protein in a cell line of preadipocytes. Specifically, they reported that both telmisartan and irbesartan activate PPAR-γ messenger ribonucleic acid (mRNA) transcription and protein expression in 3T3-L1 human adipocytes, suggesting that these drugs, independently from AT 1 -receptor antagonism also act as selective PPAR-γ ligands in these cells. Notably, losartan induced similar effects only at a concentration almost 10 times higher. In these same studies the transcription intermediary factor 2 (TIF-2), an adipogenic co-activator implicated in PPAR-γ mediated lipid uptake and storage, increased the transcriptional activity of PPAR-γ and this effect was potentiated by irbesartan but not by telmisartan. 14 Thus, different PPAR-γ agonists that selectively modulate specific groups of genes through differential release and/or recruitment of specific gene-activators or generepressors may have different effects on receptor activation cascades. In vitro investigations indicate that the concentration of telmisartan required to produce 50% activity as PPAR-γ activator was 4.5 μmol/L. Interestingly, this concentration is comparable to those measured in plasma upon therapeutic doses. Other AIIAs (including irbesartan, candesartan, valsartan, olmesartan, eprosartan and the active metabolite of losartan) on the contrary showed significant activation of PPAR-γ at concentrations much higher than those measured in plasma at therapeutic doses. 14 The potential effects of Ang II receptor blockade (ARB) on adipose cell biology are of considerable interest because these agents are frequently used to treat hypertension in patients that are prone to obesity, type 2 diabetes and the so called metabolic syndrome, as will be discussed in detail later. As proposed by Sharma and coworkers, 15 the ability of AIIAs to promote the differentiation of small, metabolically efficient adipocytes could be crucial in contributing to the lower rates of new onset of diabetes in patients treated with these agents compared with other antihypertensive drugs. These findings suggest that these compounds may have important effects on adipocyte size, that might go beyond ARB, and may have the potential to increase energy expenditure and protect against increases in weight gain and fat accumulation.
Several clinical studies have been conducted to compare the antihypertensive effects of telmisartan with those of ACE-Is. 10 Clinical evidence demonstrates that the antihypertensive effect of telmisartan is not inferior to or even greater than most widely used ACE-Is. Treatment of hypertensive patients with telmisartan at doses of 40 or 80 mg/day once-daily was comparable to enalapril and lisinopril at conventional doses in controlling blood pressure, 12, 16 and slightly more effective than perindopril and ramipril. [17] [18] Regarding its safety profile it has been shown that telmisartan is well tolerated in long-term use, inducing less treatment-related adverse events than ACE-Is. These events have been reported to range from 9-7% in telmisartan recipients in several studies while in ACE-I-treated patients the incidence of treatment-related events ranged from 10-27%. 10 In these studies adverse events were comparable in patients treated with telmisartan and in those receiving placebo. 10 Regarding serious adverse events, telmisartan treatment has been shown to slightly but not significantly increase the risk as compared to placebo, and the most commonly reported of these events were hyperuricaemia and hypokalaemia. 19
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Effects of telmisartan in type 2 diabetes and the metabolic syndrome
A large number of patients who have indications for treatment with ACE-Is or AIIAs are affected by the metabolic syndrome, which is characterised by visceral obesity, insulin resistance, dyslipidaemia and elevated blood pressure. This condition is also, as this implies, associated with thrombotic, atherogenic and pro-inflammatory cardiovascular events. As mentioned previously, the evidence that Ang II inhibits human preadipocyte differentiation 20 would suggest that pharmacological antagonism of the reninangiotensin system (RAS) could prevent diabetes complications by modulating adipogenesis, with redistribution of fat from visceral deposits to lessdangerous subcutaneous deposits. The observation that in obese patients there is an increased activity of the RAS further support the proposition that renin-angiotensin blockade may be the treatment of choice in obese patients with the metabolic syndrome. 21, 22 In the attempt to interfere pharmacologically with adipogenesis in these patients, activators of the different isoforms of PPAR (-α, -γ and -δ) have been developed and tested. A class of such compounds, the glitazones, however seems to increase incidence of adverse effects such as weight gain, fluid retention and heart failure. 23, 24 Thus, the demonstration that some AT 1 -receptor blockers are capable of only partially activating PPAR-γ could theoretically be of great interest as a novel approach to address the multifactorial components of the metabolic syndrome. Differences in molecular conformation of partial PPAR-γ agonists, as compared to full agonists, might explain the differences in receptor activation with consequent differences in gene expression and in adipogenic potential. 25, 26 In this context Sugimoto and coworkers 27 recently provided experimental evidence in the rat that telmisartan was effective in decreasing adipocyte size with reduction of hepatic fat storage and increased energy expenditure, all effects that are likely derived from the ability of telmisartan to act as a partial PPAR-γ agonist. In these studies telmisartan was more potent in inducing these effects than other Ang II antagonists. At the moment, however, it has to be considered that telmisartan could be superior to the other compounds simply because it is a stronger antagonist of Ang II receptors.
Whatever the mechanism, the observation that telmisartan may have specific actions on adipocyte proliferation and function is of substantial interest. There is also evidence that partial agonists of PPAR-γ could be effective in these patients, also because mitochondrial dysfunction plays a key role in the development of obesity, insulin resistance, and type 2 diabetes, all factors associated with sedentary life-styles and aging. However, despite all these suggestions regarding the use of telmisartan in these patients, most evidence is based on experimental studies and it is known that there are differences between adipocyte function and tissue RAS between rodents and humans. Thus, more detailed knowledge of the mechanisms of action of this drug is needed to safely and effectively transfer experimental results to clinical conditions.
Fat accumulation and increased risk of vascular disease in patients affected by the metabolic syndrome seem to be linked by adiponectin, an endogenous modulator of vascular remodelling. 28 This molecule is known to inhibit the expression of adhesion molecules in endothelial cells, to inhibit tumour necrosis factor-alpha (TNF-α) expression in adipose tissue and in macrophages, and to prevent macrophage-tofoam cell transformation. In addition, adiponectin inhibits vascular smooth muscle cell proliferation by directly binding to the PDGF-BB receptor. 29 Finally, adiponectin-knockout mice exhibited severe neointimal thickening and increased proliferation of vascular cells in mechanically injured arteries and developed neointimal hyperplasia. 30 All these data strongly support the hypothesis that increasing adiponectin may be an important therapeutic strategy for the treatment of the metabolic syndrome, and the prevention of atherosclerosis and related cardiovascular events. Since partial agonists of PPAR-γ may ameliorate insulin sensitivity by augmenting adiponectin and leptin activity it may be possible with this treatment to prevent weight gain, improve lipid profile, prevent steatosis and fibrosis at the hepatic and pancreatic level, and to enhance vascular and cardiac protection as well as protection of other organs. Conceptually molecules that are at the same time AIIAs and PPAR-γ partial agonists, may have double potential. On one hand the selective block of AT 1 -receptors is expected to block the deleterious action of Ang II and probably to promote the activation of the , by increased levels of Ang II, leading to suppression of inflammatory molecules, oxidative stress and preservation of endothelial function. 31, 32, 33 On the other hand, selective activation of PPAR-γ can induce similar effects with suppression of inflammatory molecules, oxidative stress and preservation of endothelial function.
The potential effects of ARB on Ang II blockade, AT 2 activation, adipose tissue biology, body weight and insulin resistance are of considerable interest. Not all molecules of this class of drugs, however, show the same potential beneficial effects. Very recently Sugimoto et al. 27 compared the effects of telmisartan and valsartan on body weight, food intake, energy expenditure, fat accumulation and triglyceride levels in rats fed a high-fat, high-carbohydrate diet. Of interest, while telmisartan increased caloric expenditure and protected against dietary-induced weight gain valsartan did not induce these beneficial effects. In rats treated with telmisartan, absolute food intake was significantly lower than in control animals and also in valsartan treated rats. Telmisartan reduced the accumulation of visceral fat, decreased adipocyte size and was also associated with a significant reduction in hepatic triglyceride levels as compared to untreated controls. By contrast, animals treated with valsartan did not show statistically significant differences in these parameters as compared to untreated controls. Since telmisartan, but not valsartan, increased the expression of genes in skeletal muscle that are involved in mitochondrial energy metabolism, it has been suggested that molecules like telmisartan may have a significant impact on fat accumulation and energy metabolism, and can help to protect against visceral obesity and weight gain. 27 Finally, in addition to these favourable effects, telmisartan seem also to modulate insulin resistance and lipid profile. The evidence comes from in vitro studies on differentiated 3T3-L1 adipocyte cultures in which telmisartan, at concentrations comparable to those seen in patients' plasma, significantly increased glucose uptake, independently of the presence of insulin. 14, 34 Valsartan at the same doses did not show significant effects on glucose uptake. In addition, telmisartan but not valsartan significantly increased GLUT4 protein expression in a dose-dependent manner. These peculiar effects of telmisartan at cellular level may potentially play a role in insulin-sensitising activity. The so far available in vivo studies seem to confirm these potential effects. Thus, in a rat model of diet-induced insulin resistance 34 telmisartan significantly lowered glucose levels. However, it has to be considered that in patients with moderate hypertension and impaired insulin sensitivity associated with type 2 diabetes, telmisartan induced beneficial effects on insulin sensitivity tests but failed to significantly affect glucose profile. 35, 36 More clinical evidence is required to derive definitive conclusions on this matter. For this purpose controlled clinical trials are in progress. Thus, the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial will investigate whether AIIAs help in protecting against development of diabetes by virtue of AT1-receptor blockade. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) will establish whether telmisartan exerts more effective actions because of its intrinsic PPAR-γ activity. The results of these trials are expected in 2007.
Renoprotective effects of Ang II antagonism
In the last five years there has been an important change in the pattern of prescription of antihypertensive therapies, with a five-fold increase in the prescriptions of ACE-Is and only a 20% increase in the prescriptions of beta blockers. It is notable that the prescriptions of statins has almost doubled in this period. There is the general acknowledgement, however, that ACE-Is which are now prescribed in a large proportion of patients with hypertension can cause cough in a significant percentage of them and this potential side effect limits their use and usefulness. To overcome this limitation AIIAs are then largely prescribed based on their lower incidence of cough rather than due to evidence of stronger antihypertensive effects or other organ protective effects.
Few studies have directly compared the renoprotective effects of ARB and ACE-Is in patients with type 2 diabetes. Recently Barnett et al. 26 reported the results of a prospective, randomised, multicentre, double-blind, five-year study based on 250 subjects with type 2 diabetes and early nephropathy assigned to receive either telmisartan (80 mg daily, in 120 subjects) or the ACE-I enalapril (20 mg daily, in 130 subjects). The primary end point of the study was the change in glomerular filtration rate (GFR) determined by measuring the plasma clearance of iohexol between the baseline value and the last available value during the five-year treatment period. Secondary end points of the study included annual changes in GFR, serum creatinine, urinary albumin excretion and blood pressure control. The rates of end-stage renal disease and of cardiovascular events, as well as the incidence of death from all causes, were monitored during the study. At the end of the study period the change in the GFR, with telmisartan averaged -17.9 ml/min/1.73 m 2 . In patients treated with enalapril GFR decrement averaged -14.9 ml/min/1.73 m 2 with a treatment difference of -3.0 ml/min/1.73 m 2 , however, the difference in mean GFR in favour of enalapril was greater than the predefined level. These authors indicated that telmisartan was not inferior to enalapril in slowing renal disease progression. Beside the primary end point, the effects of the two agents on the secondary endpoints were not significantly different by the end of the study. Overall, the results of the controlled clinical trial showed that longterm treatment with telmisartan provided comparable renoprotective efficacy as compared to enalapril in patients with type 2 diabetes with early-stage nephropathy. As far as adverse events were concerned, telmisartan showed greater tolerability as also demonstrated in other earlier comparative studies.
Beside this direct comparison, there are numerous studies that provide evidence that both ACE-Is and AIIAs are effective in protecting against deterioration of renal function. This applies not only to clinical studies but was originally observed also in animal experiments, as we have reported. 37 A different conclusion, however, can be derived by comparison of the two classes of compounds on cardiovascular events and overall mortality. Thus, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study 38 showed a relative risk of myocardial infarction or cardiovascular mortality in type 2 diabetics higher for AIIAs than for ACE inhibition. Similarly, in the meta-analysis of Strippoli et al. 39 the relative risk of all cause mortality was lower for ACE-I treatments as compared to AIIAs in the same category of patients.
Is there a role for telmisartan in the regression of renal disease?
In the last few years we used a genetic model of kidney disease progression to shed more light on the mechanisms responsible for renal disease progression and the potential effects of drugs used to prevent or slow the progression of the renal disease such as ACE-Is and AIIAs. This model is represented by the male Munich Wistar Froemter rat (MWF), a strain of rat that spontaneously develops proteinuria, renal structural changes and progressive loss of renal function. 2 In these animals ACE inhibition is able not only to prevent proteinuria and structural changes, but to completely normalise massive proteinuria and to induce regression of structural changes both at the glomerular and tubular level even if the treatment is started when the disease is already developed. More recently 7 we have collected evidence that high-dose ACE inhibition in animals with established renal dysfunction is able to reduce the extension of glomerular sclerotic changes and to increase the volume of structurally intact glomerular tissue. We suggested that ACE inhibition, counteracting the effects of Ang II, may induce tissue repair by glomerular capillary restructuring or regeneration. 6 This experimental evidence has been parallelled by clinical observations in several studies performed in patients affected by progressive proteinuric kidney diseases. 40 Thus, it has been suggested that prolonged treatment with ACE-Is can stop the progressive loss of renal function inducing the so called remission stage and in some cases also allow regression of renal disease with actual increase in renal function (GFR).
The experimental and clinical evidence suggests that adequate Ang II biological antagonism in patients affected by progressive loss in renal function may retard or even avoid the need for renal replacement therapy, such as haemodialysis or renal transplantation. Now there are two open questions on these therapeutic approaches, the first is to establish whether different molecules have different effects on the regression of the disease and the second is to establish which form of disease is effectively ameliorated by these therapies and which are less sensitive to the treatment.
The AIIA telmisartan is one of the drugs currently used to antagonise the action of Ang II by blocking the AT 1 -receptor. As mentioned previously, this drug has two potential advantages over other molecules of the same class. The first is that the pharmacologial action of telmisartan is the most long lasting, suggesting a better pharmacodynamic profile, not only for antihypertensive effects but also for Ang II blockade in general. Since the remission and regression or renal disease is strictly related to the level of Ang II antagonism, we can suggest that better and longer lasting ARB may induce greater beneficial effects in these patients. As also discussed previously, the second advantage of telmisartan is related to its effect as a partial agonist of PPAR-γ.
It has been shown 41 that PPAR-γ activation in a non-diabetic model of glomerulosclerosis leads to beneficial effects that include reduction in proteinuria, serum creatinine and glomerulosclerosis as compared to untreated controls. These effects on the sclerotic process at glomerular level seem to be different from those in vascular sclerosis and are most likely related to regulation of glomerular proliferation and decreased macrophage infiltration. PPAR-γ activation also decreased plasminogen activator inhibitor type 1 and transforming growth factorbeta production. More recently, partial agonism of PPAR-γ with telmisartan has been shown to 42 All this evidence would suggest that telmisartan may be more potent than ACE-Is or other AIIAs in protecting kidney structure and function in progressive proteinuric renal disease.
Despite interesting experimental data and theoretical considerations suggesting that telmisartan is superior to other compounds of the same class and also superior to ACE-Is, we do not yet have a formal demonstration that this is the case. In this condition it is mandatory to go back to experimental models of kidney disease to firstly investigate the effective potential of telmisartan on inducing remission of kidney structural and functional changes and to evaluate cellular and molecular mechanisms of action. If experimental research will provide direct proof of this hypothesis, clinical research may then be initiated with the aim of potentiating the effects of presently used therapies to stop the progression of kidney disease in an attempt to avoid renal replacement therapy in a significant proportion of these patients. Thus, more focussed research at experimental and clinical level is needed in this regard and it is to be hoped future studies will be available in the near future with direct proof of these concepts.
Conclusions
Experimental and clinical research has established that telmisartan has a favourable safety profile, efficiently blocks Ang II receptors and can also act as a PPAR-γ activator at concentrations normally achievable with therapeutic doses. Emerging experimental studies have revealed that this drug is associated with potentially beneficial metabolic profiles. This includes increased energy expenditure, improved lipid profile, increased insulin sensitivity, blood pressure reduction, and amelioration of the associated pro-inflammatory and pro-atherogenic risk profiles. This information provides a strategic rationale for the use of a molecule that exerts dual effects, as AIIAs and as PPAR-γ agonist, to target hypertension, renal disease progression and the metabolic syndrome with the related risk of cardiovascular events. The use of such potential therapy is also based on the fact that present therapy is not sufficient for these patients. The potential benefit for treatment of the metabolic syndrome, cardiovascular protection and prevention of related end-organ complications, such as the kidney, could be of immense clinical value.
These preliminary findings and the related theoretical considerations should motivate future studies on the ability of molecules, like telmisartan, to attenuate weight gain, reduce the risk for visceral obesity in patients with hypertension and protect against organ failure, since most of the results available have been obtained so far in in vitro systems or in animal models. Regarding protection of the kidney, formal experimental demonstration of the potential protective effects of telmisartan is still missing and it should be obtained in well established models of kidney disease in the animal, related or unrelated to diabetes. If the results of such investigations should be positive, as suggested by the considerations made above, they could be tested in clinical conditions to quantify the degree of effective kidney protection, by induction of remission or regression of progressive proteinuric renal disease. 
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